Shares of Arrowhead Pharmaceuticals Inc. ($ARWR) and Sarepta Therapeutics Inc. ($SRPT) climbed on Wednesday despite Wall ...

Arrowhead Pharmaceuticals (NASDAQ:ARWR) added ~21% in the premarket on Tuesday after the company announced a global licensing ...

Sarepta Therapeutics Inc. has a plan in place to significantly expand the diseases it treats beyond Duchenne muscular ...

Arrowhead Pharmaceuticals' stock rallied 17% due to significant pipeline developments and strategic partnerships. Learn more ...

Arrowhead (ARWR) announced a global licensing and collaboration agreement with Sarepta (SRPT). Upon closing, Arrowhead will receive $825M, ...

Strategic Sarepta partnership and FDA filing position Arrowhead for a transformative leap in RNAi therapeutics ...

H.C. Wainwright lowered the firm’s price target on Sarepta (SRPT) to $75 from $80 and keeps a Sell rating on the shares. Sarepta’s deal to ...

After Sarepta (SRPT) announced a global licensing and collaboration agreement with Arrowhead (ARWR) that adds four clinical-stage siRNA assets for rare genetic diseases, Leerink analyst Joseph ...

Needham lowered the firm’s price target on Sarepta (SRPT) to $202 from $205 and keeps a Buy rating on the shares. The deal with Arrowhead (ARWR) offers platform diversification with clear long-term ...

(RTTNews) - Arrowhead Pharmaceuticals (ARWR), a clinical-stage biotech company, announced, on Tuesday, that it has entered into a global licensing and collaboration agreement with Sarepta ...

This adjustment comes in the wake of Sarepta's licensing deal with Arrowhead Pharmaceuticals (NASDAQ:ARWR), which incorporates a variety of clinical and preclinical assets. Sarepta's partnership ...

Arrowhead Pharmaceuticals (NASDAQ:ARWR) added ~21% in the premarket on Tuesday after the company announced a global licensing and collaboration agreement with Sarepta Therapeutics (NASDAQ ...